(3,4-dichlorobenzyl)(2,2-dimethoxyethyl)amine | 845724-17-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3,4-dichlorobenzyl)(2,2-dimethoxyethyl)amine
• 英文别名: N-(3,4-dichlorobenzyl)-N-(2,2-dimethoxyethyl)amine；3,4-Dichlorobenzyl-(2,2-dimethoxyethyl)amine；N-[(3,4-dichlorophenyl)methyl]-2,2-dimethoxyethanamine
• CAS: 845724-17-6
• 化学式: C₁₁H₁₅Cl₂NO₂
• mdl: MFCD12148386
• 分子量: 264.152
• InChiKey: KATMJPBBUYIIRP-UHFFFAOYSA-N

物化性质

• 沸点：
  318.5±37.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3,4-dichlorobenzyl)(2,2-dimethoxyethyl)amine 在 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor

  摘要：

  本发明涉及一种由下式[I]所表示的含氮融合环化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，并可用作预防或治疗艾滋病的药剂，或作为抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可使其成为更有效的抗HIV剂。由于显示出整合酶特异性高抑制活性，该化合物可作为对人体安全的药物剂，仅引起较少的副作用。

  公开号：

  US20050054645A1
• 作为产物：
  描述：

  N-<(3,4-dichlorophenyl)methylene>-2,2-dimethoxyethanamine 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 (3,4-dichlorobenzyl)(2,2-dimethoxyethyl)amine
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008

文献信息

• Synthesis and algicidal activity of new dichlorobenzylamine derivatives against harmful red tides
  作者：Dubok Choi、Sunjong Yu、Seung Ho Baek、Yoon-Ho Kang、Young-Cheol Chang、Hoon Cho

  DOI：10.1007/s12257-016-0175-8

  日期：2016.6

  In the present study, we synthesized 65 dichlorobenzylamine derivatives and investigated their algicidal activity against harmful red tides. The 3,4-dichlorobenzylamine derivatives showed relatively high activity against Cochlodinium polykrikoides, Heterosigma akashiwo, Chattonella marina, and Heterocapsa circularisquama, and the synthesized compounds 27, 28, 33, 34, 35, and 36 showed the highest algicidal activity after 24 h at 0.1 ~ 1.0 μM LC50 against the four harmful algae species. To verify the safety of the compounds, acute ecotoxicology tests using the water flea (Daphnia magna) and zebrafish (Danio rerio) were conducted, and the tests confirmed that compounds 33 and 34 were not harmful because the target organisms showed high survival rates at 15 μM. The results indicate that compounds 33 and 34 are suitable substances for use in controlling harmful algae species.

  在本研究中，我们合成了65种二氯苄胺衍生物，并研究了它们对有害赤潮的藻类灭杀活性。3,4-二氯苄胺衍生物对多刺菱形藻、赤潮藻、海洋Chattonella以及圆形裙藻显示出较高的活性，而合成的化合物27、28、33、34、35和36在0.1 ~ 1.0 μM LC50条件下，在24小时后对这四种有害藻类展现出最高的藻类灭杀活性。为了验证这些化合物的安全性，我们进行了使用水蚤（Daphnia magna）和斑马鱼（Danio rerio）的急性生态毒理学测试，结果表明化合物33和34并不有害，因为目标生物在15 μM浓度下显示出较高的生存率。这些结果表明化合物33和34适合作为控制有害藻类的物质。
• NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR
  申请人：Japan Tobacco Inc.

  公开号：EP1544199A1

  公开（公告）日：2005-06-22

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及由下式[I]表示的含氮融合环化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，以及含有这种化合物的抗HIV制剂。本发明的化合物具有抑制 HIV 整合酶的活性，可用作预防或治疗艾滋病的药物，或用作抗 HIV 药物。此外，通过与蛋白酶抑制剂、逆转录酶抑制剂等其他抗艾滋病毒药物联合使用，它可以成为一种更有效的抗艾滋病毒药物。由于该化合物对整合酶具有特异性的高抑制活性，因此是一种对人体安全的药物，副作用较小。
• US7211572B2
  申请人：——

  公开号：US7211572B2

  公开（公告）日：2007-05-01
• Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
  申请人：Miyazaki Susumu

  公开号：US20050054645A1

  公开（公告）日：2005-03-10

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及一种由下式[I]所表示的含氮融合环化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，并可用作预防或治疗艾滋病的药剂，或作为抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可使其成为更有效的抗HIV剂。由于显示出整合酶特异性高抑制活性，该化合物可作为对人体安全的药物剂，仅引起较少的副作用。
• Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site
  作者：Lawrence I. Kruse、Carl Kaiser、Walter E. DeWolf、James S. Frazee、Stephen T. Ross、Joyce Wawro、Merrie Wise、Kathryn E. Flaim、John L. Sawyer

  DOI：10.1021/jm00386a008

  日期：1987.3

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.